Lead Product(s) : Fluticasone Propionate
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Nicox’s Positive FDA Meeting Shows Clear Path for NCX 4251 in Dry Eye
Details : Fluticasone propionate, the active ingredient in NCX 4251, is a well-established corticosteroid which has been marketed for more than 20 years for a number of non-ophthalmic indications, including asthma and allergic rhinitis.
Product Name : NCX 4251
Product Type : Steroid
Upfront Cash : Inapplicable
August 02, 2022
Lead Product(s) : Fluticasone Propionate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fluticasone Propionate
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Nicox Granted New Patent for NCX 4251 in Japan
Details : Newly granted patent extends the coverage for NCX 4251 in Japan to 2040 and, it covers ophthalmic suspensions comprising a specific form of fluticasone propionate nanocrystals and the method for manufacturing the ophthalmic suspensions.
Product Name : NCX 4251
Product Type : Steroid
Upfront Cash : Inapplicable
February 22, 2022
Lead Product(s) : Fluticasone Propionate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fluticasone Propionate
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : NCX 4251 is a novel and patented ophthalmic suspension of fluticasone propionate nanocrystals currently in Phase 2 development in the U.S. for patients with dry eye disease.
Product Name : NCX 4251
Product Type : Steroid
Upfront Cash : Inapplicable
February 05, 2022
Lead Product(s) : Fluticasone Propionate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fluticasone Propionate
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : NCX 4251, ophthalmic suspension of fluticasone propionate nanocrystals for the topical treatment of the eyelids in patients with acute exacerbations of blepharitis, showed statistically significant improvement or reduction in the dry eye symptoms.
Product Name : NCX 4251
Product Type : Steroid
Upfront Cash : Inapplicable
November 30, 2021
Lead Product(s) : Fluticasone Propionate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fluticasone Propionate
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Nicox is Granted Patent for Blepharitis Product Candidate NCX 4251 in Europe
Details : NCX 4251, has been issued by EPO, and its patent coverage is extended in the EU to 2040.The patent covers ophthalmic suspensions comprising a specific form of fluticasone propionate nanocrystals and the method for manufacturing the ophthalmic suspensions...
Product Name : NCX 4251
Product Type : Steroid
Upfront Cash : Inapplicable
November 17, 2021
Lead Product(s) : Fluticasone Propionate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AGN-231868
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Allergan Aesthetics
Deal Size : $5.0 million
Deal Type : Collaboration
Eurobio Scientific Receives a $430,000 Milestone Payment From Allergan
Details : During the clinical development of AGN-231868, Eurobio Scientific remains eligible to other milestone payments linked to successful transitions to further clinical stages.
Product Name : AGN-231868
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 10, 2021
Lead Product(s) : AGN-231868
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Allergan Aesthetics
Deal Size : $5.0 million
Deal Type : Collaboration
Lead Product(s) : Fluticasone Propionate
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Nicox’s NCX 4251 Mississippi Phase 2b Blepharitis Trial Reaches 50% Enrollment
Details : Mississippi is a Phase 2b clinical trial of NCX 4251, evaluating once-daily dosed NCX 4251 0.1% versus placebo in patients with acute exacerbations of blepharitis. It is expected to randomize 200 patients at clinical sites across the U.S.
Product Name : NCX 4251
Product Type : Steroid
Upfront Cash : Inapplicable
April 23, 2021
Lead Product(s) : Fluticasone Propionate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fluticasone Propionate
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : OcuMension Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Nicox’s Completes Pre-Defined Enrollment of NCX 4251 Mississippi Phase 2b Blepharitis Trial
Details : Mississippi is a Phase 2b clinical trial of NCX 4251, evaluating once-daily dosed NCX 4251 0.1% versus placebo in patients with acute exacerbations of blepharitis.
Product Name : NCX 4251
Product Type : Steroid
Upfront Cash : Inapplicable
January 06, 2021
Lead Product(s) : Fluticasone Propionate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : OcuMension Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fluticasone Propionate
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Nicox Initiates Phase 2b Trial of NCX 4251, a Potential First-in-Class Treatment for Blepharitis
Details : NCX 4251 has first-in-class potential, addressing the unmet medical need of patients with blepharitis. Mississippi Phase 2b trial will evaluate once-daily dosed NCX 4251 0.1% versus placebo in patients with acute exacerbations of blepharitis.
Product Name : NCX 4251
Product Type : Steroid
Upfront Cash : Inapplicable
December 15, 2020
Lead Product(s) : Fluticasone Propionate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bimatoprost
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : OcuMension Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Nicox to Receive €15 Million and Half of the Cost of the Second NCX 470 Phase 3 Clinical Trial
Details : Nicox will conduct both of its planned Phase 3 clinical trials, Mont Blanc and Denali, as multi-regional clinical trials in U.S. and China.
Product Name : NCX 470
Product Type : HPAPI
Upfront Cash : $3.3 million
November 03, 2020
Lead Product(s) : Bimatoprost
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : OcuMension Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement